All questionsClinical trials: Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer5 questions · 4 sourcesClinical trialsHow was the DATROWAY TROPION-Breast01 trial designed?“TROPION-Breast01: A multicenter, open-label, randomized phase 3 trial of DATROWAY (6 mg/kg IV Q3W; n=365) vs investigator’s choice of chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine; n=367) in 732 previously treated patients with unresectable or metastatic HR+/HER2− breast cancer. Patients must have progressed on and deemed not suitable for further endocrine therapy, and received 1 or 2 lines of prior chemotherapy in the unresectable or metastatic disease setting. Stratification factors included 1 or 2 previous lines of chemotherapy, prior CDK4/6 inhibitor use, and geography. Dual primary endpoints were PFS (BICR) and OS.1,2” (opens the source at this quote in a new tab)CopyFlag“No prior ADC use was permitted.2” (opens the source at this quote in a new tab)CopyFlagStudy resultsHow long does DATROWAY delay breast cancer progression compared with chemotherapy (TROPION-Breast01)?“Superior mPFS1† 6.9 months with DATROWAY (n=365) VS 4.9 months with chemotherapy (n=367) (HR=0.63; 95% CI: 0.52, 0.76; P<0.0001) Median OS (dual primary endpoint): 18.6 months with DATROWAY and 18.3 months with chemotherapy (HR=1.01; 95% CI: 0.83, 1.22). Data was not statistically significant.1” (opens the source at this quote in a new tab)CopyFlag“TROPION-Breast01 had dual primary endpoints of PFS (BICR) and OS (see below for summary of study design). The study was positive if either PFS or OS results were statistically significant.1,7” (opens the source at this quote in a new tab)CopyFlagDo patients live longer on DATROWAY than on chemotherapy (TROPION-Breast01)?“Median overall survival1 18.6 months with DATROWAY and 18.3 months with chemotherapy HR=1.01 (95% CI: 0.83, 1.22). Data was not statistically significant.” (opens the source at this quote in a new tab)CopyFlagWhat was the DATROWAY response rate in TROPION-Breast01?“The major efficacy outcomes were progression-free survival (PFS) as assessed by blinded independent central review (BICR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 and overall survival (OS). Additional efficacy outcomes included confirmed objective response rate (ORR) and duration of response (DOR) by BICR.” (opens the source at this quote in a new tab)CopyFlag“Table 13: Efficacy Results in TROPION-Breast01 DATROWAY (n=365) Chemotherapy (n=367) Progression-Free Survival a Number of events (%) 212 (58) 235 (64) Progressive Disease 201 (55) 218 (59) Death 11 (3) 17 (5) Median, months (95% CI) 6.9 (5.7, 7.4) 4.9 (4.2, 5.5) Hazard ratio (95% CI) b 0.63 (0.52, 0.76) p-value c, d < 0.0001 Overall Survival Number of events (%) 223 (61) 213 (58) Median, months (95% CI) 18.6 (17.3, 20.1) 18.3 (17.3, 20.5) Hazard ratio (95% CI) b 1.01 (0.83, 1.22) p-value c NS Confirmed Objective Response Rate a n (%) 133 (36) 84 (23) (95% CI) 31, 42 19, 28” (opens the source at this quote in a new tab)CopyFlagWhat percentage of DATROWAY patients had no progression at 9 and 12 months (TROPION-Breast01)?“Exploratory landmark data: The following analysis is descriptive only, as the trial was not powered to assess a statistical difference between treatment groups at these time points. Therefore, the clinical significance of these data is not known.2 At 9 months, 38% of patients were progression free with DATROWAY and 19% with chemotherapy2 At 12 months, 26% and 15% were progression free, respectively2” (opens the source at this quote in a new tab)CopyFlag